Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev).
Pastina P, Nardone V, Botta C, Croci S, Tini P, Battaglia G, Ricci V, Cusi MG, Gandolfo C, Misso G, Zappavigna S, Caraglia M, Giordano A, Aldinucci D, Tassone P, Tagliaferri P, Pirtoli L, Correale P. Pastina P, et al. Among authors: cusi mg. Oncotarget. 2017 Aug 24;8(44):75904-75913. doi: 10.18632/oncotarget.20411. eCollection 2017 Sep 29. Oncotarget. 2017. PMID: 29100279 Free PMC article.
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro.
Correale P, Cusi MG, Del Vecchio MT, Aquino A, Prete SP, Tsang KY, Micheli L, Nencini C, La Placa M, Montagnani F, Terrosi C, Caraglia M, Formica V, Giorgi G, Bonmassar E, Francini G. Correale P, et al. Among authors: cusi mg. J Immunol. 2005 Jul 15;175(2):820-8. doi: 10.4049/jimmunol.175.2.820. J Immunol. 2005. PMID: 16002679 Free article.
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.
Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, Aquino A, Micheli L, Nencini C, Ferrari F, Giorgi G, Bonmassar E, Francini G. Correale P, et al. Among authors: cusi mg. J Clin Oncol. 2005 Dec 10;23(35):8950-8. doi: 10.1200/JCO.2005.12.147. Epub 2005 Aug 1. J Clin Oncol. 2005. PMID: 16061910 Clinical Trial.
Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine.
Correale P, Del Vecchio MT, Renieri T, Di Genova G, La Placa M, Remondo C, Savellini GG, Terrosi C, Zurbriggen R, Amacker M, Francini G, Cusi MG. Correale P, et al. Among authors: cusi mg. Cancer Lett. 2008 May 18;263(2):291-301. doi: 10.1016/j.canlet.2008.01.018. Epub 2008 Mar 4. Cancer Lett. 2008. PMID: 18291576
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial).
Correale P, Tagliaferri P, Fioravanti A, Del Vecchio MT, Remondo C, Montagnani F, Rotundo MS, Ginanneschi C, Martellucci I, Francini E, Cusi MG, Tassone P, Francini G. Correale P, et al. Among authors: cusi mg. Clin Cancer Res. 2008 Jul 1;14(13):4192-9. doi: 10.1158/1078-0432.CCR-07-5278. Clin Cancer Res. 2008. PMID: 18593999 Clinical Trial.
167 results